Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross Blue Shield SC Actimmune Prior Auth Pol…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Actimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, coverage criteria, and utilization controls for Actimmune (INJ 100MCG/0.5ML) for medically accepted indications (chronic granulomatous disease and severe malignant osteopetrosis) for Blue Cross Blue Shield - South Carolina members and providers.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyActimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionObtain prior authorization and document diagnosis of CGD or severe malignant osteopetrosis for Actimmune requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2diagnoses required
    12 monthsstandard coverage
    1products affected
    Yes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    continuation allowed

    Coverage Criteria and Decision Logic

    Initial and continuation coverage

    Covered when ALL of the following are met

    Actimmune coverage criteria: 1) Documentation of a diagnosis of chronic granulomatous disease (CGD) OR severe malignant osteopetrosis (SMO); 2) Prior authorization obtained for Actimmune (INJ 100MCG/0.5ML); 3) Coverage duration requested up to 12 months; 4) Continuation requests considered if prior therapy was previously approved.

    Prerequisite Part D drug is not required for initial approval.

    PAH (Alyq) Initial Therapy

    Alyq (PAH) — initial criteria

    Alyq PAH initial: Diagnosis of pulmonary arterial hypertension (PAH) AND PAH is symptomatic AND one of: (A) diagnosis confirmed by right heart catheterization OR (B) patient is currently on therapy for PAH.

    Prescribed by or in consultation with a pulmonologist or cardiologist; initial coverage 6 months; reauthorization 12 months; reauth requires positive clinical response.

    PAH and CTEPH Initial Therapy (Adempas)

    Adempas — initial criteria for PAH and CTEPH

    PAH criteria options: Diagnosis of PAH AND PAH is symptomatic AND one of: (A) diagnosis confirmed by right heart catheterization OR (B) patient is currently on any therapy for PAH.

    Prescribed by or in consultation with a pulmonologist or cardiologist; initial coverage 6 months; reauth 12 months; reauth requires positive clinical response.

    CTEPH criteria options: Either (A) both: diagnosis of inoperable or persistent/recurrent CTEPH AND CTEPH is symptomatic; OR (B) patient is currently on any therapy for CTEPH.

    Initial coverage 6 months; reauth 12 months; reauth requires positive clinical response.

    Everolimus Indication Criteria

    Everolimus (Afinitor) — indication-specific criteria

    SEGA associated with TSC: Diagnosis of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) that requires therapeutic interventionPatient age >= 1 year for SEGA

    Coverage 12 months; approve continuation of prior therapy.

    Renal cell carcinoma: Diagnosis of advanced renal cell carcinoma AND trial and failure, contraindication, or intolerance to sunitinib (SUTENT) or sorafenib (NEXAVAR)

    Coverage 12 months.

    Pancreatic neuroendocrine tumor (pNET): Diagnosis of progressive pancreatic neuroendocrine tumor that is unresectable, locally advanced, or metastatic

    Coverage 12 months.

    Episodic and Chronic Migraine Criteria (Aimovig)

    Aimovig — migraine prevention

    Episodic Migraine (EM) initial: Diagnosis of episodic migraine with greater than or equal to 4 migraine days per monthPatient age >= 18 years

    Initial coverage 6 months; reauth 12 months; reauth requires positive response and decreased use of acute migraine medications; not to be used with another CGRP inhibitor for prevention.

    Chronic Migraine (CM) initial: Diagnosis of chronic migraine after consideration and discontinuation of medication overuse headache contributors with greater than or equal to 8 migraine days per monthPatient age >= 18 years

    Initial coverage 6 months; reauth 12 months; reauth requires positive response and monitoring for medication overuse headache.

    Akeega Indication Criteria

    Akeega — metastatic prostate cancer with BRCA mutation

    Akeega metastatic prostate cancer: Diagnosis of metastatic prostate cancer that is deleterious or suspected deleterious BRCA-mutated AND used in combination with prednisone AND used with a GnRH agent where applicable

    Coverage duration 12 months; approve continuation of prior therapy.

    NSCLC Product Criteria (Alecensa, Alunbrig)

    ALCENSA and ALUNBRIG — NSCLC

    NSCLC diagnosis: Diagnosis of non-small cell lung cancer (NSCLC)

    Coverage duration 12 months; approve continuation of prior therapy.

    Alpha-1 Antitrypsin Deficiency Criteria

    Prolastin-c — AAT deficiency

    AAT deficiency initial: Diagnosis of congenital alpha-1 antitrypsin (AAT) deficiency AND diagnosis of emphysema AND continued conventional treatment for emphysema AND one of: (1) PiZZ, PiZ(null), or Pi(null)(null) homozygous phenotypes OR (2) other rare AAT genotypes associated with pre-treatment serum AAT less than 11 µM/L (or corresponding mg/dL equivalents)Pre-treatment serum AAT < 11 µM/L (or <80 mg/dL by radial immunodiffusion or <57 mg/dL by nephelometry)

    Coverage 12 months initial and reauth; reauth requires positive clinical response and continued conventional treatment.

    Dalfampridine (Ampyra) - Initial and Reauthorization

    Dalfampridine (Ampyra) — initial and reauthorization

    Dalfampridine initial criteria: 1) Diagnosis of multiple sclerosis (MS). 2) Physician confirmation that the patient has difficulty walking (e.g., timed 25-foot walk). 3) One of: EDSS score ≤ 7 OR not restricted to using a wheelchair (if EDSS not measured).

    Initial coverage 6 months; reauth 12 months with physician confirmation of walking improvement for reauthorization.

    Arikayce - Initial

    Arikayce — initial criteria

    Arikayce initial criteria: 1) Diagnosis of Mycobacterium avium complex (MAC) lung disease. 2) Use as part of a combination antibacterial regimen. 3) Patient did not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen.

    Coverage duration 12 months; prescribed by or in consultation with an infectious disease specialist.

    Augtyro - Indications

    Augtyro — indications

    Augtyro NSCLC (ROS1): Diagnosis of locally advanced or metastatic NSCLC with ROS1 rearrangement-positive tumor(s).

    Coverage duration 12 months; approve continuation of prior therapy.

    Augtyro solid tumors (NTRK): Diagnosis of locally advanced, metastatic, or unresectable solid tumor with an NTRK gene fusion and disease progressed following prior treatment or no satisfactory alternative treatments.

    Coverage duration 12 months; approve continuation of prior therapy.

    Arformoterol - COPD maintenance

    Arformoterol — COPD maintenance

    Arformoterol criteria: Diagnosis of chronic obstructive pulmonary disease (COPD) AND use for maintenance treatment of bronchoconstriction in patients with COPD (including chronic bronchitis and emphysema).

    Coverage duration 12 months; subject to Part B vs Part D review.

    Avtozma - Rheumatology and SSc-ILD indications (partial)

    Avtozma — rheumatology and SSc-ILD indications (partial)

    RA initial: Diagnosis of moderately to severely active rheumatoid arthritis AND either (a) trial and failure/contraindication/intolerance to two of the listed agents (eg, Enbrel, formulary adalimumab, Orencia, Rinvoq, Xeljanz) OR (b) continuation of prior therapy.

    Initial duration 6 months; reauth 12 months; prescribed by or in consultation with a rheumatologist.

    GCA initial: Diagnosis of giant cell arteritis (GCA).

    Initial 6 months; reauth 12 months; prescribed by or in consultation with a rheumatologist.

    SJIA/PJIA initial: Diagnosis of systemic juvenile idiopathic arthritis (SJIA) or polyarticular juvenile idiopathic arthritis (PJIA) with required prior trials or continuation of prior therapy as specified.

    Initial 6 months; reauth 12 months; prescribed by or in consultation with rheumatology.

    Initial Therapy / Coverage conditions (examples)

    Examples of initial therapy and coverage conditions

    Prescriber requirement example: Prescribed by or in consultation with the appropriate specialist (eg, rheumatologist for RA/SSc-ILD; dermatologist for plaque psoriasis initiation).

    Specialist prescriber requirements apply as listed per indication.

    Coverage duration examples: Initial coverage duration: 6 months for selected indications such as RA, GCA, SJIA, PJIA, SSc-ILD; reauthorization: 12 months when patient demonstrates positive clinical response.

    Reauthorization requires demonstration of clinical benefit for specified indications.

    Benlysta SLE initiation example: Diagnosis of active systemic lupus erythematosus (SLE) AND autoantibody positive (ANA ≥1:80 or anti-dsDNA ≥30 IU/mL) AND current use of at least one standard-of-care therapy.ANA ≥1:80 or anti-dsDNA ≥30 IU/mL

    Prescribed by or in consultation with a rheumatologist for initiation.

    Continuation / Reauthorization

    Continuation / reauthorization

    Continuation — Ayvakit: Approve for continuation of prior therapy when initial diagnostic and laboratory criteria were met.

    Coverage duration 12 months.

    Continuation — Balversa: Approve for continuation of prior therapy when initial criteria including genetic testing and prior therapy are met.

    Coverage duration 12 months.

    Continuation — Besremi: Diagnosis of polycythemia vera meeting listed lab criteria and prerequisite therapy where applicable; approve continuation when prior authorization criteria previously met.

    Coverage duration 12 months.

    Bronchitol Initial Therapy

    Bronchitol — initial therapy

    Bronchitol initial: Diagnosis of cystic fibrosis (CF) AND patient has passed the Bronchitol Tolerance Test (BTT)

    Prescribed by or in consultation with a pulmonologist or specialist; initial coverage 6 months; reauth 12 months; reauth requires positive clinical response.

    Brukinsa Indication Criteria

    Brukinsa — indication-specific criteria

    MCL: Diagnosis of mantle cell lymphoma (MCL) AND patient has received at least one prior therapy for MCL

    Coverage duration 12 months; approve continuation of prior therapy; prerequisite Part D drug may be required per entry.

    MZL: Diagnosis of marginal zone lymphoma (MZL) that is relapsed or refractory AND patient has received at least one prior anti-CD20 regimen

    Coverage duration 12 months.

    CLL/SLL: Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) AND contraindication or intolerance to acalabrutinib (Calquence)

    Coverage duration 12 months.

    FL: Diagnosis of follicular lymphoma (FL) that is relapsed or refractory AND used in combination with obinutuzumab and patient has received at least two prior lines of systemic therapy

    Cablivi Indication Criteria

    Cablivi — aTTP criteria

    Cablivi — aTTP: Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) AND first dose administered by a healthcare provider as a bolus IV injection AND used in combination with immunosuppressive therapy AND either used with plasma exchange OR patient completed plasma exchange less than 59 days ago.

    Prescribed by or in consultation with a hematologist or oncologist; coverage duration 3 months.

    Cabometyx Indication Criteria

    Cabometyx — tumor-specific criteria

    RCC: Diagnosis of renal cell carcinoma (RCC)

    May require trial and failure, contraindication, or intolerance to sorafenib (Nexavar); coverage duration 12 months.

    HCC: Diagnosis of hepatocellular carcinoma (HCC)

    May require prior therapy documentation; coverage duration 12 months.

    DTC: Diagnosis of differentiated thyroid cancer (DTC) with disease progression following prior VEGFR-targeted therapy and refractory or ineligible for radioactive iodine

    Age >=12 for DTC; coverage duration 12 months.

    Neuroendocrine tumors: Diagnosis of pancreatic or extra-pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic and previously treated

    Calquence Indication Criteria

    Calquence — indication-specific criteria

    MCL first-line: Diagnosis of mantle cell lymphoma (MCL) AND patient has received no prior therapy for MCL AND patient is ineligible for autologous HSCT AND used in combination with bendamustine and rituximab.

    Coverage duration 12 months.

    MCL relapsed: Diagnosis of MCL AND patient has received at least one prior therapy for MCL.

    Coverage duration 12 months.

    CLL/SLL: Diagnosis of CLL or SLL.

    Coverage duration 12 months.

    Caplyta Indication Criteria

    Caplyta — indication-specific criteria

    Schizophrenia: Diagnosis of schizophrenia AND trial and failure, contraindication, or intolerance to two specified oral generic atypical antipsychotics (eg, asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)

    Coverage duration 12 months.

    Bipolar disorder: Diagnosis of bipolar I or II disorder with depressive episodes AND trial and failure, contraindication, or intolerance to quetiapine or olanzapine; used as monotherapy or adjunct with lithium/valproate.

    Coverage duration 12 months.

    MDD adjunctive: Major depressive disorder used as adjunctive therapy with an antidepressant AND trial and failure, contraindication, or intolerance to aripiprazole and quetiapine.

    Coverage duration 12 months.

    Caprelsa Indication Criteria

    Caprelsa — medullary thyroid cancer criteria

    MTC: Diagnosis of metastatic or unresectable locally advanced medullary thyroid cancer with symptomatic or progressive disease.

    Coverage duration 12 months.

    Cayston Indication Criteria

    Cayston — cystic fibrosis criteria

    Cayston CF initial: Evidence of Pseudomonas aeruginosa in the lungs AND patient is 7 years of age or older for initial CF use.

    Reauthorization requires evidence of benefit (improvement or decreased pulmonary exacerbations); coverage duration per entry.

    Cerdelga Indication Criteria

    Cerdelga — Gaucher disease type 1 criteria

    Cerdelga initial: Diagnosis of Gaucher disease type 1 AND documentation of CYP2D6 metabolizer status (extensive, intermediate, or poor metabolizer) as detected by an FDA-cleared test AND patient is 18 years of age or older.

    Coverage duration 12 months; approve continuation of prior therapy.

    Cerdelga: Initial Therapy

    Cerdelga — initial therapy

    Cerdelga initial coverage: 1) Diagnosis of Gaucher disease type 1; 2) CYP2D6 metabolizer status documented (EM, IM, or PM) by FDA-cleared test; 3) Age 18 years or older.

    Coverage duration 12 months; prerequisite Part D drug not required.

    Chenodal: Initial/Reauthorization

    Chenodal — initial and reauthorization

    Chenodal initial coverage: 1) Diagnosis of radiolucent gallstones; 2) Well-opacifying gallbladder on oral cholecystography; 3) Trial and failure, contraindication, or intolerance to ursodiol; 4) Patient is not a candidate for surgery; 5) Stones are not calcified (radiopaque) or radiolucent bile pigment.

    Prescribed by or in consultation with a gastroenterologist; initial and reauth coverage 12 months; reauth requires re-evaluation (eg, oral cholecystogram or ultrasound).

    Cholbam: Indication-specific criteria

    Cholbam — indication-specific criteria

    Bile acid synthesis disorders (BAS) initial: Diagnosis of a bile acid synthesis disorder due to a single enzyme defect confirmed by abnormal urinary bile acid analysis by mass spectrometry OR molecular genetic testing consistent with the diagnosis.

    Initial coverage 4 months; reauth 12 months with evidence of clinical response.

    Peroxisomal disorders (PD) initial: Diagnosis of a peroxisomal disorder by abnormal urinary bile acid analysis or molecular genetic testing AND patient exhibits at least one of: liver disease, steatorrhea, or complications from decreased fat-soluble vitamin absorption; used as adjunctive therapy.

    Initial 4 months; reauth 12 months with demonstrated improvement in liver function; prescribed by specialist.

    Ciclopirox: Onychomycosis criteria

    Ciclopirox lacquer — onychomycosis criteria

    Ciclopirox coverage: 1) No lunula (matrix) involvement; 2) Diagnosis of onychomycosis (toenail or fingernail) confirmed by KOH, culture, or histology; 3) If toenail: mild-to-moderate disease involving at least one target toenail; 4) Trial and failure, contraindication, or intolerance to oral terbinafine (>=6 weeks for fingernails; >=12 weeks for toenails).

    Coverage duration 48 weeks; prerequisite Part D drug required.

    Cinryze: HAE prophylaxis criteria

    Cinryze — HAE prophylaxis criteria

    HAE Type I/II diagnostic confirmation: Diagnosis confirmed by: a) C4 level below lower limit of normal AND b) C1-INH antigenic or functional level below lower limit of normal (Type I/II HAE).
    HAE-nl-C1INH diagnostic confirmation: Diagnosis confirmed by: a) normal C4 and C1-INH levels AND b) either presence of a causative gene mutation detected by FDA-cleared or CLIA-approved test OR confirmed family history of recurrent angioedema.
    Cinryze coverage conditions: 1) Use is for prophylaxis against HAE attacks; 2) Not used in combination with other approved prophylactic HAE treatments; 3) Prescribed by or in consultation with an immunologist or allergist; 4) Patient age ≥ 6 years for prophylaxis.

    Coverage duration initial and reauth 12 months; reauth requires positive clinical response.

    Cobenfy: Coverage

    Cobenfy — coverage

    Cobenfy coverage: Intolerance to two of the listed oral generic formulary atypical antipsychotics (eg, aripiprazole, asenapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone); approve continuation of prior therapy when applicable.

    Prerequisite Part D drug required per entry.

    Cometriq: Coverage

    Cometriq — metastatic medullary thyroid cancer

    Cometriq coverage: Diagnosis of metastatic medullary thyroid cancer (MTC).

    Coverage duration 12 months; approve continuation of prior therapy.

    Copiktra: Coverage

    Copiktra — CLL/SLL coverage

    Copiktra coverage: Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that is relapsed or refractory AND trial and failure, contraindication, or intolerance to at least two prior therapies for CLL/SLL.

    Prerequisite Part D drug required per entry.

    Cosentyx IV Initial Therapy

    Cosentyx — initial therapy (selected indications)

    Plaque psoriasis (initial): Diagnosis of moderate to severe plaque psoriasis AND one of: ≥3% BSA involvement OR severe scalp psoriasis OR palmoplantar/facial/genital involvement; AND minimum 4-week trial and failure/contraindication/intolerance to one topical therapy (corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor).BSA >= 3%

    Prescribed by or in consultation with a dermatologist; initial coverage 6 months.

    Psoriatic arthritis (initial): Diagnosis of active psoriatic arthritis with at least one of: actively inflamed joints, dactylitis, enthesitis, axial disease, or active skin/nail involvement.

    Prescribed by or in consultation with a rheumatologist or dermatologist; initial coverage 6 months.

    Ankylosing spondylitis (initial): Diagnosis of active ankylosing spondylitis AND minimum 1-month trial and failure/contraindication/intolerance to one NSAID at maximally tolerated doses.1 month NSAID trial

    Reauthorization/Continuation Therapy

    Cosentyx — reauthorization/continuation therapy

    Cosentyx reauthorization: Patient demonstrates positive clinical response to therapy as evidenced by objective or symptomatic improvement from baseline (examples vary by indication: reduced joint counts, reduced BSA, reduced abscess/nodule count, improved lab or functional measures).

    Reauthorization duration: 12 months.

    Cosentyx IV Initial Therapy

    Cosentyx IV — specific initial pathways

    PsA IV initial pathways: Either (a) trial and failure/contraindication/intolerance to two listed agents (eg, Cosentyx SC, Enbrel, formulary adalimumab, Orencia, Otezla, Skyrizi, Sotyktu, Tremfya, formulary ustekinumab, Rinvoq, Xeljanz) OR (b) continuation of prior therapy.TF/C/I to 2 agents

    Prescriber: rheumatologist or dermatologist; initial coverage 6 months.

    AS IV initial pathways: Either (a) trial and failure/contraindication/intolerance to two listed agents (eg, Cosentyx SC, Enbrel, formulary adalimumab, Rinvoq, Xeljanz) OR (b) continuation of prior therapy.TF/C/I to 2 agents

    Prescriber: rheumatologist; initial coverage 6 months.

    nr-axSpA IV initial pathways: Either (a) trial and failure/contraindication/intolerance to both Cosentyx SC and Rinvoq OR (b) continuation of prior therapy; objective signs of inflammation required for diagnosis.

    Initial and Off-Label Indications

    Initial and off‑label indications (examples)

    Muscle spasm (acute): Diagnosis of muscle spasm associated with acute, painful musculoskeletal conditions.

    Coverage duration 4 weeks.

    Fibromyalgia (off-label): Use to treat fibromyalgia-related symptoms (eg, difficulty sleeping).

    Coverage duration 12 months.

    Acute temporomandibular disorder (off-label): Diagnosis of acute temporomandibular disorder AND pain on palpation of the lower jaw muscle AND used in combination with an NSAID.

    Coverage duration 4 weeks.

    Age restriction: PA applies to patients 65 years or older for cyclobenzaprine formulations.

    Prescriber must acknowledge anticholinergic risks.

    Diacomit - Initial/Continuation

    Diacomit — Dravet syndrome

    Diacomit initial/continuation: Diagnosis of seizures associated with Dravet syndrome AND used in combination with clobazam AND patient weight ≥ 7 kg AND patient age ≥ 6 months AND prescribed by or in consultation with a neurologist.weight ≥ 7 kg; age ≥ 6 months

    Coverage duration 12 months; continuation of prior therapy allowed.

    Doptelet - TPPP and ITP criteria

    Doptelet — TPPP and ITP criteria (summarized)

    Doptelet indications: TPPP: diagnosis of thrombocytopenia in a patient with chronic liver disease scheduled for a procedure with baseline platelet count <50,000/mcL (coverage 1 month). ITP (initial): diagnosis of chronic/relapsed/refractory/persistent ITP with baseline platelet count <30,000/mcL AND trial and failure/contraindication/intolerance to at least one of corticosteroids, immunoglobulins, or splenectomy (coverage initial and reauth 12 months). ITP reauth: patient demonstrates positive clinical response (increase in platelet count adequate to avoid clinically important bleeding).platelet thresholds as specified

    Prerequisite Part D drug required for some criteria; prescriber typically hematologist.

    Dupixent - Multiple indications and criteria

    Dupixent — multiple indications and criteria (selected)

    Eosinophilic asthma (EA) initial: Diagnosis of moderate-to-severe asthma with eosinophilic phenotype (baseline blood eosinophils ≥150 cells/mcL) AND either ≥2 exacerbations requiring systemic corticosteroids in past 12 months OR prior asthma-related hospitalization in past 12 months; age- and therapy-specific controller regimen requirements apply.eosinophils ≥150 cells/mcL

    Prescribed by or in consultation with pulmonologist or allergist/immunologist; coverage durations per indication.

    EoE initial: Diagnosis of eosinophilic esophagitis with esophageal dysfunction symptoms AND ≥15 intraepithelial eosinophils per high power field AND exclusion of other causes AND patient weight ≥15 kg AND trial and failure/contraindication/intolerance to an 8-week PPI or topical esophageal corticosteroid.≥15 eos/hpf; weight ≥15 kg

    Prescriber: gastroenterologist or allergist/immunologist; reauth requires clinical or histologic improvement.

    Atopic dermatitis (AD) initial:

    Ebglyss - Atopic dermatitis

    Ebglyss — atopic dermatitis

    Ebglyss initial: Diagnosis of moderate-to-severe atopic dermatitis AND patient age ≥12 years AND patient weight ≥40 kg AND one of: BSA involvement ≥10% OR SCORAD ≥25 AND trial and failure/contraindication/intolerance to a minimum 30-day supply of medium or higher potency topical corticosteroid (14-day supply referenced for topical corticosteroids elsewhere).age ≥12; weight ≥40 kg; BSA ≥10% or SCORAD ≥25

    Prescribed by or in consultation with a dermatologist; initial coverage 6 months; reauth 12 months and requires documented positive clinical response.

    Emgality - Migraine and cluster headache indications

    Emgality — migraine and cluster headache indications

    Episodic migraine (EM) initial: Diagnosis of episodic migraine with ≥4 migraine days per month (for 120 mg/mL strength) in adults; will not be used concurrently with another injectable CGRP inhibitor; initial coverage 6 months.≥4 migraine days/month

    Reauth 12 months requires positive response and decreased use of acute migraine meds.

    Chronic migraine (CM) initial: Diagnosis of chronic migraine with ≥8 migraine days per month (for 120 mg/mL strength) in adults after evaluation for medication overuse headache; will not be used with another injectable CGRP inhibitor; initial coverage 6 months.≥8 migraine days/month

    Reauth 12 months requires positive response.

    Episodic cluster headache (ECH) initial: Diagnosis of episodic cluster headache with at least 2 cluster periods lasting 7–365 days separated by pain-free periods ≥3 months; 100 mg/mL strength only; adult patients; initial coverage 3 months.

    Empaveli - PNH and glomerulopathy criteria

    Empaveli — PNH and glomerulopathy criteria

    PNH initial: Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH).

    Prescribed by or in consultation with a hematologist or oncologist; coverage duration 12 months; reauth requires positive clinical response.

    C3G or primary IC-MPGN initial: Diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN); for primary IC-MPGN patient must not have had a kidney transplant; patient must have been treated with a maximally tolerated dose of ACE inhibitor, ARB, or SGLT2 inhibitor for at least 12 weeks prior to initiating Empaveli.12-week trial of ACEi/ARB/SGLT2

    Coverage duration 12 months; prerequisite Part D drug required per excerpt.

    Empaveli / C3G/PNH criteria

    Empaveli — Complement/PNH indications (initial and reauth)

    Empaveli initial - PNH: Diagnosis of PNH is required.

    Prescriber: hematologist/oncologist; coverage 12 months.

    Empaveli initial - C3G/primary IC-MPGN: Diagnosis of C3G or primary IC-MPGN; for primary IC-MPGN patient must not have had a kidney transplant AND patient has been treated with maximally tolerated ACEi/ARB/SGLT2 for at least 12 weeks prior to initiation.12 weeks prior RAAS or SGLT2 therapy

    Coverage duration 12 months.

    Empaveli reauth: Patient demonstrates positive clinical response to therapy; for primary IC-MPGN, patient continues maximally tolerated ACEi/ARB/SGLT2 therapy and must not have had kidney transplant.

    Coverage duration 12 months.

    Enbrel initial criteria

    Enbrel — initial criteria (selected indications)

    RA initial: Diagnosis of moderately to severely active rheumatoid arthritis AND minimum 3-month trial and failure/contraindication/intolerance to one conventional therapy (methotrexate, leflunomide, or sulfasalazine) at maximally tolerated doses.3 months trial

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months; reauth 12 months.

    PJIA initial: Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis AND minimum 6-week trial and failure/contraindication/intolerance to methotrexate or leflunomide at maximally tolerated doses.6 weeks trial

    Prescribed by or in consultation with a rheumatologist.

    Plaque psoriasis initial: Diagnosis of moderate to severe chronic plaque psoriasis AND at least 3% BSA involvement OR severe scalp/palmoplantar/facial/genital involvement AND trial and failure/contraindication/intolerance to a minimum 30-day supply (14 days for topical corticosteroids) of specified topical therapies.

    Enbrel reauthorization

    Enbrel — reauthorization

    Enbrel reauth — RA/PJIA: Patient demonstrates positive clinical response evidenced by reduction in total active (swollen and tender) joint count from baseline OR improvement in symptoms (eg, pain, stiffness, inflammation) from baseline.

    Coverage duration 12 months.

    Enbrel reauth — PsA/Psoriasis: Patient demonstrates positive clinical response evidenced by reduction in total active joint count, improvement in symptoms, or reduction in BSA involvement from baseline.

    Coverage duration 12 months.

    Enbrel reauth — AS: Patient demonstrates positive clinical response evidenced by improvement in disease activity, lab values (ESR/CRP), function, axial status, or total active joint count from baseline.

    Coverage duration 12 months.

    Endari criteria

    Endari — sickle cell disease

    Endari initial: Diagnosis of sickle cell disease AND patient has had two or more painful sickle cell crises within the past 12 months.≥2 crises in prior 12 months

    Coverage duration per entry; approve for continuation of prior therapy.

    Ensacove criteria

    Ensacove — ALK-positive NSCLC

    Ensacove initial: Diagnosis of non-small cell lung cancer (NSCLC) that is locally advanced or metastatic AND disease is ALK rearrangement-positive by FDA-approved or CLIA-approved test AND patient has not previously received an ALK inhibitor.no prior ALK inhibitor

    Coverage duration 12 months; approve continuation of prior therapy.

    Epclusa criteria

    Epclusa — chronic hepatitis C

    Epclusa initial: Diagnosis of chronic hepatitis C AND not used in combination with another HCV direct-acting antiviral agent; criteria applied consistent with current AASLD/IDSA guideline.

    Prescribed by or in consultation with specialist as listed; coverage duration 12–24 weeks per guideline.

    Epidiolex criteria

    Epidiolex — seizure disorder indications

    Epidiolex indications: Diagnosis of seizures associated with Lennox‑Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) AND trial of, contraindication, or intolerance to two formulary anticonvulsants as applicable.Age ≥1 year for LGS/DS/TSC

    Prescribed by or in consultation with a neurologist; coverage duration 12 months; continuation allowed.

    Epoetin alfa criteria

    Epoetin alfa — indication‑specific laboratory and clinical requirements

    Anemia with CKD (initial): Diagnosis of chronic kidney disease (CKD) AND anemia with Hct <30% or Hgb <10 g/dL collected within 30 days of request AND either patient is on dialysis without ESRD or patient not on dialysis with Hb decline that indicates likely need for RBC transfusion.Hct <30% or Hgb <10 g/dL

    Coverage durations per indication; adequate iron stores required (ferritin >100 mcg/L and TSAT >20%).

    Anemia with chemo (initial): Non-myeloid malignancy receiving chemotherapy AND anemia with Hct <30% or Hgb <10 g/dL collected within prior 2 weeks AND other causes ruled out.Hct <30% or Hgb <10 g/dL

    Coverage initial 3 months; adequate iron stores required.

    Preoperative use: Patient scheduled for elective, non-cardiac, non-vascular surgery AND Hgb >10 to ≤13 g/dL AND patient is at high risk for perioperative transfusions and unwilling or unable to donate autologous blood.

    Indication-specific initial and reauthorization criteria

    Epoetin alfa — indication‑specific initial and reauthorization (examples)

    HCV-related anemia (initial): Diagnosis of HCV infection AND anemia by labs (Hct <36% or Hgb <12 g/dL) collected within 30 days AND patient is receiving ribavirin with interferon/peg-interferon.Hct <36% or Hgb <12 g/dL

    Reauth rules specified in policy.

    HIV-related anemia (initial): Anemia by labs (Hgb <12 g/dL or Hct <36%) collected within 30 days AND serum erythropoietin ≤500 mU/mL AND receiving zidovudine therapy or diagnosis of HIV.Hgb <12 g/dL or Hct <36%; EPO ≤500 mU/mL
    MDS (initial): Diagnosis of myelodysplastic syndrome AND serum erythropoietin level ≤500 mU/mL OR diagnosis of transfusion-dependent MDS.EPO ≤500 mU/mL or transfusion-dependent MDS

    Asthma (initial)

    Asthma — initial

    Severe asthma initial: Diagnosis of severe asthma AND eosinophilic phenotype defined by baseline peripheral blood eosinophils ≥150 cells/µL AND one of: (a) ≥2 asthma exacerbations requiring systemic corticosteroids in past 12 months OR (b) prior asthma-related hospitalization in past 12 months AND age- and therapy-specific controller regimen documentation as specified per age group.eosinophils ≥150 cells/µL

    Prescribed by or in consultation with a pulmonologist or allergist/immunologist; initial coverage 6 months.

    Asthma (reauthorization)

    Asthma — reauthorization

    Asthma reauth: Patient demonstrates positive clinical response to therapy as documented by the prescriber.positive clinical response

    Coverage duration 12 months.

    EGPA (initial)

    EGPA — initial

    EGPA initial: Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) AND patient is currently receiving corticosteroid therapy unless contraindicated or intolerant.

    Prescribed by or in consultation with pulmonologist, rheumatologist, or allergist/immunologist; coverage duration 12 months.

    HES (initial)

    HES — initial

    HES initial: Diagnosis of hypereosinophilic syndrome (HES) with other non-hematologic secondary causes ruled out AND patient is FIP1L1-PDGFRA-negative AND pre-treatment blood eosinophil count ≥1000 cells/µL AND trial and failure/contraindication/intolerance to corticosteroid or cytotoxic/immunosuppressive therapy.>=1000 cells/µL

    Prescribed by or in consultation with allergist/immunologist or hematologist; coverage duration 12 months.

    EGPA/HES (reauthorization)

    EGPA/HES — reauthorization

    EGPA/HES reauth: Patient demonstrates positive clinical response to therapy as documented by the prescriber.positive clinical response

    Coverage duration 12 months.

    Fruzaqla - Initial/Line therapy criteria

    Fruzaqla — metastatic colorectal cancer initial/line therapy

    Fruzaqla initial: Diagnosis of metastatic colorectal cancer AND prior treatment with (A) fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy AND (B) anti-VEGF biological therapy.

    Coverage duration 12 months; approve continuation of prior therapy.

    Tumor molecular/sequence requirements: Either: (A) tumor is RAS mutant; OR (B) tumor is RAS wild-type AND patient previously treated with an anti-EGFR biologic AND with either trifluridine/tipiracil (Lonsurf) or regorafenib (Stivarga).

    Prerequisite Part D drug required per entry.

    Gavreto - Indication and biomarker criteria

    Gavreto — indication and biomarker criteria

    Gavreto NSCLC indication: Diagnosis of NSCLC AND presence of metastatic RET gene fusion-positive tumor(s) detected by FDA-approved or CLIA-approved test.

    Coverage duration 12 months; approve continuation of prior therapy.

    Gavreto thyroid indication: Diagnosis of advanced or metastatic thyroid cancer with RET fusion-positive tumor(s) requiring systemic therapy AND radioactive iodine-refractory disease or radioactive iodine therapy is not appropriate.

    Age restriction for thyroid cancer: patient ≥12 years; coverage duration 12 months.

    Gamastan - Immunization requirement

    Gamastan — immunization requirement

    Gamastan immunization: Patient requires immunization for hepatitis A, measles, rubella, or varicella and will receive the minimum effective dose and appropriate frequency for the diagnosis.

    Coverage per clinical indication; prerequisite Part D drug not required.

    MS agents - Indication, prescriber, and reauthorization criteria

    MS agents — indication, prescriber, and reauthorization criteria

    MS initial: Diagnosis of a relapsing form of multiple sclerosis (eg, clinically isolated syndrome, relapsing‑remitting, secondary progressive with active disease) AND prescribed by or in consultation with a neurologist.

    Not used in combination with another disease‑modifying therapy for MS; coverage duration 12 months.

    MS reauth: Patient demonstrates positive clinical response to therapy (eg, stability in radiologic disease activity, reduced clinical relapses) for reauthorization.

    Coverage duration 12 months.

    Gomekli - Indication criteria

    Gomekli — indication criteria

    Gomekli initial/continuation: Diagnosis of neurofibromatosis type 1 AND presence of inoperable plexiform neurofibromas.

    Coverage duration 12 months; approve continuation of prior therapy.

    Gleevec - Indications

    Gleevec — labeled indications (examples)

    Gleevec allowed diagnoses: One of: Philadelphia chromosome (Ph+)/BCR‑ABL‑positive chronic myelogenous leukemia (CML); Ph+/BCR‑ABL+ acute lymphoblastic leukemia (ALL); gastrointestinal stromal tumor (GIST); dermatofibrosarcoma protuberans (unresectable, recurrent, or metastatic); hypereosinophilic syndrome or chronic eosinophilic leukemia; myelodysplastic/myeloproliferative disease.

    Coverage duration 12 months; approve continuation of prior therapy.

    Glycopyrrolate - Peptic ulcer criteria

    Glycopyrrolate — peptic ulcer criteria

    Glycopyrrolate initial: Diagnosis of peptic ulcer AND either (1) patient is receiving a proton‑pump inhibitor (PPI) OR (2) patient has contraindication/intolerance to PPIs AND is receiving concomitant H2‑receptor antagonist therapy; prescribed by or in consultation with a gastroenterologist.

    Initial and reauth coverage duration 3 months; reauth requires non-healing ulcer or symptomatic improvement.

    Gomekli Coverage Criteria

    Gomekli — PA coverage criteria (repeat for PA requirements)

    Gomekli PA criteria: Diagnosis of neurofibromatosis type 1 AND plexiform neurofibromas that are inoperable.

    Prescriber specialty and documentation per product; coverage duration 12 months.

    Genotropin Coverage Criteria

    Genotropin — growth hormone product criteria (overview)

    Pediatric growth indications: Indication‑specific diagnostic thresholds (eg, height >2.0 SD below midparental height or >2.25 SD below population mean, growth velocity >2 SD below mean, delayed skeletal maturation) with supporting documentation (eg, bone age, GH stimulation tests, IGF‑1 levels) as applicable.height/growth velocity/bone age thresholds as specified

    Prescribed by or in consultation with an endocrinologist; coverage duration 12 months; reauthorization requires evidence of positive response and expected adult height not yet attained.

    HER2-targeted NSCLC Agents Coverage Criteria

    HER2‑targeted NSCLC agents — coverage criteria (examples)

    Hernexeos (HER2 NSCLC): Diagnosis of non‑squamous NSCLC that is unresectable or metastatic AND presence of HER2 (ERBB2) tyrosine kinase domain activating mutation detected by FDA‑approved or CLIA‑approved test.

    Coverage duration 12 months; approve continuation of prior therapy.

    Hyrnuo (HER2 NSCLC): Diagnosis of non‑squamous NSCLC that is locally advanced or metastatic AND HER2 activating mutation detected by FDA‑approved or CLIA‑approved test AND patient received prior systemic therapy.

    Prerequisite Part D drug may be required; coverage duration 12 months.

    Humira Coverage Criteria

    Humira — selected indication-specific initial and reauthorization criteria

    Humira RA initial: Diagnosis of moderately to severely active rheumatoid arthritis AND minimum 3‑month trial and failure/contraindication/intolerance to one conventional therapy (methotrexate, leflunomide, or sulfasalazine) at maximally tolerated doses.3 months trial

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months; reauth 12 months.

    Humira PsO initial: Diagnosis of moderate to severe chronic plaque psoriasis with ≥3% BSA involvement or severe scalp/palmoplantar/facial/genital involvement AND trial and failure/contraindication/intolerance to specified topical therapies (minimum 30‑day supply; 14 days for topical corticosteroids).30 days topical trial (14 days for topical corticosteroids)

    Prescriber: dermatologist; initial coverage 6 months; reauth requires positive clinical response.

    Humira reauthorization:

    Ibrance and Ibtrozi Coverage Criteria

    Ibrance and Ibtrozi — oncology coverage examples

    Ibrance: Diagnosis of breast cancer documented in the medical record.

    Coverage duration 12 months; approve continuation of prior therapy.

    Ibtrozi: Diagnosis of non‑small cell lung cancer (NSCLC) that is locally advanced or metastatic AND presence of ROS1 rearrangement‑positive tumor detected by an FDA‑approved or CLIA‑approved test.

    Coverage duration 12 months; approve continuation of prior therapy.

    Products Affected and Code Listings

    Products Affected / Drug formulationsNDC
    Actimmune INJ 100MCG/0.5MLProduct formulation listed under Products Affected
    Products listed (example)NDC | proprietary
    Benlysta INJ 200MG/MLProduct listing as presented
    Products listedNDC | proprietary
    Braftovi CAPS 75MGProduct listing as presented
    Briviact / Brivaracetam productsNDC | proprietary
    Brivaracetam SOLNProduct listing as presented
    Brivaracetam TABSProduct listing as presented
    Briviact SOLNProduct listing as presented
    Briviact TABSProduct listing as presented
    Covered NDC/Product listings (SC)NDCCovered
    Cosentyx INJ 150MG/MLProduct listing — SC formulation (150 mg/mL)
    Cosentyx INJ 75MG/0.5MLProduct listing — SC formulation (75 mg/0.5 mL)
    Cosentyx Sensoready PenDevice presentation
    Cosentyx UnoreadyDevice presentation
    Covered NDC/Product listings (IV)NDCCovered
    Cosentyx INJ 125MG/5MLIV formulation listing
    Affected product descriptionsmixed
    NDC/HCPCS/CPT not specifiedDocument lists product strengths but does not provide billing codes.
    Product NDC/Strength listingsmixed
    Dupixent INJ 200MG/1.14MLProduct and strength listed in document
    Dupixent INJ 300MG/2MLProduct and strength listed in document
    Product names (other)mixed
    EbglyssProduct name listed
    Product names (other)mixed
    EmgalityProduct name listed
    Product names (other)mixed
    EmpaveliProduct name listed
    Additional product names appearing in excerptmixed
    DiacomitProduct name listed
    DopteletProduct name listed
    DuleraProduct name listed
    Ebgllyss (Ebglyss)Product name listed
    EmgalityProduct name listed
    EmpaveliProduct name listed
    Products mentioned (no explicit codes in excerpt)mixed
    NDC/HCPCS not specifiedProduct listings provided (e.g., Enbrel formulations, L-glutamine pack, Sofosbuvir/velpatasvir, Epidiolex, Procrit) but exact codes not listed in this excerpt.
    No explicit CPT/HCPCS/NDC codes listed in this sectionmixed
    No codes listed
    Fruzaqla codesmixed
    N/ANo specific CPT/HCPCS/ICD codes listed for Fruzaqla in this section
    Gavreto codesmixed
    N/ANo specific CPT/HCPCS/ICD codes listed for Gavreto in this section
    Multiple sclerosis agents codesmixed
    N/ANo procedure or diagnosis codes listed for fingolimod or glatiramer acetate here
    Humira NDC/packagingNDC
    Humira INJ 10MG/0.1MLHumira injection 10MG/0.1ML
    Humira INJ 20MG/0.2MLHumira injection 20MG/0.2ML
    Humira INJ 40MG/0.4MLHumira injection 40MG/0.4ML
    Humira INJ 40MG/0.8MLHumira injection 40MG/0.8ML
    Humira Pediatric Crohns Disease Starter Pack INJ 0, 80MG/0.8MLHumira pediatric Crohn's starter pack
    Humira PenHumira prefilled pen
    Growth hormone productsmixed
    GenotropinGenotropin (growth hormone)
    Genotropin MiniquickGenotropin Miniquick
    Other specialty products listedmixed
    GomekliGomekli product listing
    HernexeosHernexeos product listing
    HyrnuoHyrnuo product listing
    IbranceIbrance product listing
    IbtroziIbtrozi product listing
    Products listed in this excerptmixed
    IbtroziProduct name listed under 'Products Affected'
    IclusigProduct name listed under 'Products Affected'
    IdhifaProduct name listed under 'Products Affected'
    IgalmiProduct name listed under 'Products Affected'
    Imbruvica CAPS/SUSP/TABSProduct names and formulations listed
    ImkeldiProduct name listed under 'Products Affected'
    InbrijaProduct name listed under 'Products Affected'
    IncrelexProduct name listed under 'Products Affected'
    InflectraProduct name listed under 'Products Affected'
    inv-121: Serum AAT level — numeric threshold
    Serum AAT level thresholdPre-treatment serum AAT < 11 µM/L (equivalent to <80 mg/dL by radial immunodiffusion or <57 mg/dL by nephelometry)
    Associated genotypesHomozygous PiZZ, PiZ(null), or Pi(null)(null) OR other rare AAT genotypes linked to low AAT levels
    Clinical requirement

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Actimmune — prior authorization and duration

    Prior authorization is required for Actimmune (INJ 100MCG/0.5ML); coverage duration is 12 months and continuation of prior therapy may be approved.

    • Coverage duration: 12 months
    • Continuation of prior therapy allowed
    Prior Authorization

    Product-specific prior authorization required

    Submit a prior authorization request with product-specific clinical documentation demonstrating the patient meets the product's indication-specific criteria and any prescriber restrictions noted.

    • Product-specific criteria include documented diagnosis and any required prior therapy or specialty prescriber/consultation.
    • Initial and reauthorization durations commonly specified (e.g., 6 or 12 months).

    Policy Definitions and Background Notes

    Actimmune (interferon gamma‑1b) is listed as a specialty product with narrow, indication‑specific coverage. The policy requires documentation of one of two defined diagnoses: chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO). The Actimmune segment sets a standard coverage duration of 12 months, allows approval for continuation of prior therapy when previously authorized, and explicitly records that no prerequisite Part D drug is required for initial approval. Off‑label uses and exclusion lists are shown as N/A in this Actimmune entry in the excerpt.

    inv-274: Required Medical Information — Actimmune diagnosis list (CGD, SMO)
    Required diagnoses list for ActimmuneChronic granulomatous disease (CGD) OR severe malignant osteopetrosis (SMO)
    PA requirementPrior authorization required for Actimmune (INJ 100MCG/0.5ML)
    Coverage duration12 months for approved requests
    inv-275: AAT deficiency criteria (definition)

    Policy Revision History

    2026-08-01policy_effective

    Policy effective date updated to 08/01/2026; coverage criteria and product listings effective on this date.

    2026-07-02policy_reviewLatest

    Policy content last revised/reviewed on 07/02/2026 reflecting updates across product-specific criteria and Formulary ID 26216 (Version 15).

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyActimmune (interferon gamma-1b) — Prior Authorization and Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionObtain prior authorization and document diagnosis of CGD or severe malignant osteopetrosis for Actimmune requests.
    SourceLink
    On This Page
    Coverage Criteria and Decision LogicProducts Affected and Code ListingsPrior Authorization, Documentation, and Denial RisksPolicy Definitions and Background NotesPolicy Revision History
    Renal angiomyolipoma:
    Diagnosis of renal angiomyolipoma in the setting of TSC

    Coverage 12 months.

    Breast cancer: Diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer AND trial and failure, contraindication, or intolerance to letrozole (FEMARA) or anastrozole (ARIMIDEX)

    Coverage 12 months.

    GI or lung NET: Diagnosis of progressive, well-differentiated, non-functional neuroendocrine tumor of GI or lung origin that is unresectable, locally advanced, or metastatic

    Coverage 12 months.

    SSc-ILD initial:
    Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) with exclusion of other causes AND either HRCT pattern consistent with SSc-ILD or surgical lung biopsy plus HRCT consistent with SSc-ILD.

    Initial 6 months; reauth 12 months; prescribed by or in consultation with appropriate specialist.

    Coverage duration 12 months.

    Coverage duration 12 months.

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months.

    TF/C/I to Cosentyx SC and Rinvoq

    Prescriber: rheumatologist; initial coverage 6 months.

    Diagnosis of moderate-to-severe atopic dermatitis AND one of: BSA ≥10% OR SCORAD ≥25 AND trial and failure/contraindication/intolerance to specified topical/systemic therapies; patient weight and age thresholds apply.
    BSA ≥10% or SCORAD ≥25

    Prescriber: dermatologist or allergist/immunologist; coverage durations as listed.

    cluster period frequency/duration as specified

    Reauth 12 months requires documented positive response; not used with another injectable CGRP inhibitor.

    BSA >=3% or severe site involvement

    Prescribed by or in consultation with a dermatologist; initial coverage 6 months.

    AS initial: Diagnosis of active ankylosing spondylitis AND minimum 1-month trial and failure/contraindication/intolerance to one NSAID at maximally tolerated doses.1 month trial

    Prescribed by or in consultation with a rheumatologist.

    Hgb >10 to ≤13 g/dL

    Coverage duration 1 month.

    HCV/HIV/MDS specific requirements: Specific lab thresholds apply (eg, HCV: Hct <36% or Hgb <12 g/dL within 30 days; HIV/MDS: serum erythropoietin ≤500 mU/mL where indicated) AND adequate iron stores (ferritin >100 mcg/L and TSAT >20%). Off‑label uses (except MDS, HCV) will not be approved if Hgb >10 g/dL or Hct >30%.Ferritin >100 mcg/L and TSAT >20%; EPO ≤500 mU/mL where specified

    Reauthorization requires maintenance or improvement in Hct/Hgb per criteria.

    Patient demonstrates positive clinical response to therapy evidenced by disease‑specific objective or symptomatic improvement (examples vary by indication).

    Reauth durations vary by indication (commonly 12 months).

    Diagnosis of congenital AAT deficiency with clinical emphysema and continued conventional treatment for emphysema
    inv-122: Autoantibody positivity (SLE) — lab threshold
    Autoantibody positivity definitionAnti-nuclear antibody (ANA) titer ≥ 1:80 OR anti-dsDNA ≥ 30 IU/mL
    Clinical contextRequired for initiation of Benlysta for active SLE
    Concomitant therapyPatient must be currently receiving at least one standard-of-care treatment for active SLE
    inv-123: Platelet count (Ayvakit)
    Platelet threshold (general)Platelet count ≥ 50 x 10^9/L for systemic mastocytosis indications (Ayvakit)
    TPPP threshold (Doptelet)Baseline platelet count < 50,000/mcL for thrombocytopenia prior to planned procedure (TPPP)
    ITP threshold (Doptelet)Baseline platelet count < 30,000/mcL for ITP initial requests
    inv-124: Plaque psoriasis BSA threshold
    Plaque psoriasis BSA threshold>= 3% body surface area involvement
    Alternate severity criteriaSevere scalp psoriasis or palmoplantar/facial/genital involvement may qualify as moderate-to-severe disease
    Prior topical therapy requirementMinimum 4-week trial and failure/contraindication/intolerance to one topical therapy (eg, corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor)
    inv-125: Initial coverage duration (common metric)
    Standard initial coverage duration6 months (common initial duration for many indications e.g., Cosentyx, Benlysta initial uses)
    Documentation timeframeInitial coverage periods are aligned with requirement to provide baseline diagnostic and lab documentation at time of request
    Continuation allowanceInitial approvals may allow continuation of prior therapy when documented (per-product specifics apply)
    inv-126: Reauthorization coverage duration (common metric)
    Standard reauthorization duration12 months (typical reauthorization/continuation period)
    Reauth evidence requirementReauthorization generally requires demonstration of positive clinical response from baseline (examples vary by indication)
    Common exceptionsSome products have shorter or indication-specific reauth periods (see product-specific criteria) but 12 months is the common metric
    Prior Authorization

    PA required for listed specialty drugs

    Obtain prior authorization for specialty products listed in the policy; include indication-specific documentation and request the coverage duration indicated (often 12 months).

    • Approval contingent on meeting the product's diagnostic and prior-therapy requirements.
    • Many products allow continuation of prior therapy when prior approval criteria were previously met.
    Prior Authorization

    Avtozma — submit indication and diagnostic evidence

    For Avtozma requests, provide documentation of the specific rheumatologic or SSc‑ILD diagnosis and required supporting tests (e.g., HRCT or biopsy for SSc‑ILD) and either trials/failures of listed agents or an attestation why trials are inappropriate.

    • Prescriber: prescribed by or in consultation with a rheumatologist for RA, GCA, SJIA, PJIA; appropriate specialist for SSc‑ILD.
    • Initial coverage typically 6 months; reauthorization 12 months with evidence of clinical response.
    Prior Authorization

    PA and prescriber restrictions for listed specialty products

    Prior authorization is required for the specialty products in this section; initial SSc‑ILD and other indications may require specialist prescribing or consultation and the durations shown.

    • Initial durations commonly 6 months for listed rheumatology indications; reauthorization 12 months.
    • Document trials/failures or rationale for not attempting specified prior therapies when required.
    Prior Authorization

    Bronchitol — PA and BTT documentation

    Prior authorization for Bronchitol requires documentation of a cystic fibrosis diagnosis and that the patient passed the Bronchitol Tolerance Test (BTT); initial approvals are for 6 months with reauthorization at 12 months.

    • Include evidence the patient passed the BTT.
    • Reauthorization requires demonstration of benefit.
    • Prescribed by or in consultation with a pulmonologist or specialist.
    Prior Authorization

    Brukinsa — PA and prior‑therapy documentation

    Prior authorization for Brukinsa requires documentation of the specific lymphoma/leukemia diagnosis and prior therapy history (e.g., prior therapy for MCL or anti‑CD20 regimen for MZL); coverage duration is 12 months.

    • Document prior lines of therapy or intolerance/contraindication where required.
    • Many Brukinsa indications require prior Part D prerequisite therapy per the entry.
    Prior Authorization

    Cablivi — PA must include administration and aTTP details

    Prior authorization for Cablivi requires documentation of acquired thrombotic thrombocytopenic purpura (aTTP), confirmation that first dose will/were administered by a healthcare provider as a bolus IV injection, and combination therapy/plasma exchange details; coverage duration is 3 months.

    • Document use in combination with immunosuppressive therapy and plasma exchange status (ongoing or completed <59 days).
    • Prescribed by or in consultation with a hematologist/oncologist.
    Prior Authorization

    Cabometyx — PA and prior‑therapy evidence required

    For Cabometyx prior authorization, provide diagnosis of the relevant malignancy and documentation of prior targeted therapy failures or contraindications (e.g., prior sorafenib for some RCC indications); coverage duration is 12 months.

    • Document prior VEGFR‑targeted therapy failure for DTC or prior sorafenib where specified.
    • Include tumor type and prior systemic therapy history.
    Prior Authorization

    Calquence — PA with diagnosis and prior‑therapy/transplant info

    Prior authorization for Calquence requires documentation of the indicated diagnosis (e.g., mantle cell lymphoma, CLL/SLL) and prior therapy/transplant eligibility status as applicable; coverage duration is 12 months.

    • Document whether patient is treatment‑naïve or previously treated and transplant eligibility when relevant.
    • Approve continuation of prior therapy when criteria previously met.
    Prior Authorization

    Caplyta — PA requires documented prior antipsychotic trials

    Caplyta PA requests must include the labeled psychiatric diagnosis and documentation of trial and failure, contraindication, or intolerance to the specified oral generic atypical antipsychotics per indication; coverage duration is 12 months.

    • Specify which prior agents were tried and the reason for failure/contraindication/intolerance.
    • Approve continuation of prior therapy when applicable.
    Prior Authorization

    Caprelsa — PA requires MTC diagnosis and disease status

    Caprelsa prior authorization requires documentation of metastatic or unresectable locally advanced medullary thyroid cancer with symptomatic or progressive disease; coverage duration is 12 months.

    • Document disease status (symptomatic or progressive) and prior treatments as applicable.
    Prior Authorization

    Cayston — PA requires pathogen evidence and age

    Cayston prior authorization requires evidence of Pseudomonas aeruginosa in the lungs and age ≥7 years for initial CF use; reauthorization requires evidence the patient is benefiting from treatment.

    • Provide microbiology demonstrating Pseudomonas aeruginosa.
    • Document clinical benefit at reauthorization (improved outcomes or fewer exacerbations).
    Prior Authorization

    Cerdelga — PA requires CYP2D6 genotype and age

    Cerdelga prior authorization requires a diagnosis of Gaucher disease type 1 and documentation of CYP2D6 metabolizer status by an FDA‑cleared test (EM, IM, or PM); coverage duration is 12 months and age ≥18 years.

    • Include the FDA‑cleared CYP2D6 test result showing metabolizer status.
    • Confirm diagnosis of Gaucher disease type 1 and patient age ≥18.
    Documentation Required

    Cerdelga — CYP2D6 metabolizer result required

    Include documentation of CYP2D6 metabolizer status (extensive, intermediate, or poor metabolizer) when requesting Cerdelga; PA approval is granted for 12 months when criteria met.

    • Use an FDA‑cleared test result for CYP2D6 status.
    • Document that patient meets disease and age criteria.
    Prior Authorization

    Chenodal — PA requires imaging, ursodiol trial, and surgery candidacy

    Chenodal prior authorization requires diagnostic confirmation of radiolucent gallstones, visualization of a well‑opacifying gallbladder on oral cholecystography, documentation that the patient is not a surgical candidate, and trial/failure/contraindication to ursodiol; initial and reauthorization durations are 12 months.

    • Provide oral cholecystogram or ultrasound evidence and documentation regarding surgery candidacy.
    • Document the trial/failure or intolerance to ursodiol.
    Prior Authorization

    Cholbam — PA requires metabolic/genetic testing and response data

    Cholbam prior authorization requires specific diagnostic testing for bile acid synthesis disorders or peroxisomal disorders (abnormal urinary bile acid analysis by mass spectrometry or molecular genetic testing); initial coverage is 4 months with reauthorization at 12 months and evidence of clinical response.

    • Submit urinary bile acid analysis by mass spectrometry or molecular genetic testing results.
    • For reauth, provide evidence of improved liver function or clinical response.
    Prior Authorization

    Ciclopirox — PA requires mycologic confirmation and terbinafine trial

    Ciclopirox nail lacquer PA requires confirmation of onychomycosis (KOH, culture, or histology), absence of lunula involvement, and documentation of trial and failure/contraindication/intolerance to oral terbinafine (≥6 weeks fingernails, ≥12 weeks toenails); coverage duration is 48 weeks.

    • Provide laboratory confirmation (KOH, culture, or histology) and specify target nail involvement.
    • Document duration and outcome of prior oral terbinafine therapy.
    Prior Authorization

    Cinryze — PA requires HAE diagnostic labs and specialist prescriber

    Cinryze PA for HAE prophylaxis requires laboratory confirmation of HAE (low C4 and C1‑INH antigenic or functional deficiency) or diagnostic evidence for HAE‑nl‑C1INH (mutation or family history), specialist prescription/consultation, and age ≥6 years; coverage duration is 12 months.

    • Include C4 and C1‑INH antigenic or functional levels or genetic testing/family history for HAE‑nl‑C1INH.
    • Confirm prescriber is an immunologist or allergist and that Cinryze is not combined with other prophylactic HAE agents.
    Prior Authorization

    Cobenfy — PA requires intolerance to two listed antipsychotics

    Cobenfy prior authorization requires documentation that the patient is intolerant to two listed oral generic atypical antipsychotics; continuation of prior therapy may be approved.

    • List the two atypical antipsychotics attempted and reasons for intolerance.
    • Indicate if request is for continuation of previously approved therapy.
    Prior Authorization

    Cometriq — PA requires documented MTC diagnosis

    Cometriq PA requires documentation of metastatic medullary thyroid cancer diagnosis; coverage duration is 12 months and prior therapy continuation may be approved.

    • Provide pathology/clinical documentation of metastatic MTC.
    • Include prior therapy history when requesting continuation.
    Prior Authorization

    Copiktra — PA requires prior‑therapy failure documentation

    Copiktra prior authorization for relapsed/refractory CLL/SLL requires diagnosis documentation and trial/failure or intolerance to at least two prior therapies; include prior therapy details.

    • List prior CLL/SLL therapies tried and outcomes.
    • Criterion indicates prerequisite Part D drug required.
    Prior Authorization

    Cosentyx — PA and required disease severity/prior trials

    Prior authorization is required for Cosentyx products; include the indication, documentation of required diagnostic severity (e.g., BSA ≥3% for plaque psoriasis) and prior therapy trials or biologic comparators as specified.

    • Initial coverage commonly 6 months; reauthorization 12 months.
    • For some IV indications, document trial and failure/contraindication/intolerance to two specified agents or continuation of prior therapy.
    Prior Authorization

    Cyclobenzaprine — PA and prescriber risk acknowledgment for 65+

    For cyclobenzaprine in patients aged 65+, prior authorization applies and prescriber must acknowledge anticholinergic risks and document the indicated diagnosis.

    • PA applies to patients 65 years or older.
    • Prescriber must acknowledge anticholinergic risks (confusion, dry mouth, blurred vision, constipation, urinary retention).
    Prior Authorization

    Diacomit — PA requires DS diagnosis, clobazam and weight/age

    Diacomit prior authorization requires documentation of seizures associated with Dravet syndrome, concomitant clobazam use, patient weight ≥7 kg, patient age ≥6 months, and neurologist involvement; coverage is 12 months and continuation allowed.

    • Include documentation that patient is taking clobazam and weight/age evidence.
    • Prescriber: neurologist or consultation with one.
    Prior Authorization

    Doptelet — PA with platelet thresholds and prior therapy history

    Doptelet prior authorization requires indication‑specific documentation: for TPPP document chronic liver disease, planned procedure, and baseline platelets <50,000/mcL (1‑month coverage); for ITP document baseline platelets <30,000/mcL and trial/failure of corticosteroids, immunoglobulins, or splenectomy (initial/reauth 12 months).

    • Provide baseline platelet counts and prior therapy trials or contraindications.
    • Reauthorization requires evidence of platelet response to avoid bleeding.
    Prior Authorization

    Dupixent — PA requires eosinophil counts and prior controller trials

    Dupixent prior authorization requires indication‑specific laboratory/clinical thresholds (e.g., eosinophils ≥150 cells/mcL for eosinophilic asthma), prior controller therapy trials per age, and appropriate specialist involvement; document exacerbation history where indicated.

    • Include baseline eosinophil counts and prior asthma controller regimens per age group.
    • Reauthorization requires demonstrated clinical response.
    Prior Authorization

    Ebglyss — PA requires severity measures and prior topical therapy

    Ebglyss prior authorization for moderate‑to‑severe atopic dermatitis requires diagnosis, patient ≥12 years and ≥40 kg, BSA ≥10% or SCORAD ≥25, and trial/failure of specified topical/systemic therapies; initial coverage 6 months, reauth 12 months.

    • Provide weight, BSA or SCORAD, and prior topical corticosteroid trial details.
    • Prescriber: dermatologist or consultation with one.
    Prior Authorization

    Emgality — PA requires headache frequency and exclusion of concurrent CGRP therapy

    Emgality prior authorization requires diagnosis and frequency thresholds for migraine/cluster headache (e.g., ≥4 migraine days/month for episodic migraine; ≥8 for chronic), age ≥18 for EM/CM/ECH, and exclusion of concurrent injectable CGRP inhibitors; coverage durations vary (initial 3–6 months).

    • Document migraine day frequency and prior acute medication use decrease at reauth.
    • Do not combine with another injectable CGRP inhibitor for prevention.
    Prior Authorization

    Empaveli — PA requires diagnosis and prior 12‑week RAAS/SGLT2 therapy for C3G/IC‑MPGN

    Empaveli prior authorization requires documented diagnosis of PNH or C3G/primary IC‑MPGN; for C3G/IC‑MPGN the patient must have been treated with maximally tolerated ACE inhibitor/ARB or SGLT2 inhibitor for ≥12 weeks prior to initiation; coverage duration is 12 months.

    • Include documentation of prior 12‑week RAAS or SGLT2 therapy when applicable.
    • Prescriber: hematologist/oncologist for PNH; specialist for glomerulopathies.
    Prior Authorization

    PA required — common 12‑month duration and continuation allowance

    Prior authorization is required for the specialty products in this excerpt; approvals are commonly for 12 months and continuation of prior therapy is often allowed when criteria have previously been met.

    • Many products in the policy specify 12‑month approval durations.
    • Document prior approvals and prior therapy history for continuation requests.
    Documentation Required

    PA — include recent labs and treatment context for HCV/anemia

    For HCV/anemia examples and similar products, submit indication‑specific documentation including recent lab values (e.g., Hct/Hgb within specified windows) and treatment context (e.g., concurrent ribavirin plus interferon); PA is required.

    • Provide labs collected within required timeframes (e.g., within 30 days).
    • Document concurrent antiviral regimen when applicable.
    Prior Authorization

    PA for asthma/EGPA/HES — include eosinophil counts and exacerbation history

    For asthma, EGPA, and HES indications, prior authorization is required with specified initial durations (e.g., asthma initial 6 months) and reauthorization at 12 months; include baseline eosinophil levels and exacerbation/hospitalization history as required.

    • Asthma: baseline eosinophils ≥150 cells/µL and documented exacerbation history.
    • HES: pre‑treatment eosinophils ≥1000 cells/µL and FIP1L1‑PDGFRA negativity; rule out secondary causes.
    Prior Authorization

    Fruzaqla — PA requires prior chemo, anti‑VEGF and tumor RAS status

    Fruzaqla prior authorization requires documentation of metastatic colorectal cancer and prior treatment with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy plus prior anti‑VEGF therapy; include RAS status and prior anti‑EGFR and later‑line therapy history as applicable.

    • Document tumor RAS status (mutant vs wild‑type) and prior exposure to anti‑EGFR agents when RAS wild‑type.
    • Coverage duration: 12 months.
    Prior Authorization

    Gavreto — PA requires RET fusion testing and disease context

    Gavreto prior authorization requires documentation of the diagnosis and RET fusion‑positive tumor detected by an FDA‑approved or CLIA‑approved test; for thyroid cancer, document radioactive iodine‑refractory disease or that radioactive iodine is inappropriate; coverage is 12 months.

    • Include the RET fusion test result and tumor site (NSCLC or thyroid).
    • Age restriction for thyroid cancer: patient ≥12 years.
    Prior Authorization

    PA required — common 12‑month approvals (check exceptions)

    Prior authorization is required for many products in this segment; typical approval durations are 12 months though some initial approvals are 6 months — always request the duration listed for the product.

    • Check product entry for specific initial and reauthorization durations.
    • Continuation of prior therapy is commonly approved when prior criteria were met.
    Prior Authorization

    PA required — typical 12‑month approvals with exceptions

    Prior authorization is required for the products listed; approval durations are typically 12 months (exceptions such as shorter initial durations are noted in individual entries).

    • Verify product‑specific durations (e.g., Igalmi 14 days).
    • Provide documentation of prior therapy and disease severity per the product criteria.
    Note

    Prerequisite therapy — verify product entry (Actimmune: none)

    No prerequisite Part D drug is required for many product entries (including Actimmune) — verify the specific product entry to confirm whether a prerequisite Part D drug is required.

    • Actimmune: criteria does NOT require use of a prerequisite Part D drug.
    • Always confirm prerequisite therapy status in the product's entry.
    Step Therapy

    Everolimus — document specified prior therapy trials/failures

    For certain everolimus indications (e.g., renal cell carcinoma or hormone receptor‑positive breast cancer), document trial and failure, contraindication, or intolerance to the specified prior agents (sunitinib, sorafenib, letrozole, anastrozole) before approval.

    • Include documentation of prior agent names, durations, and failure/contraindication details.
    • Coverage duration typically 12 months.
    Step Therapy

    Rheumatology — prerequisite trials or attestation required

    For several rheumatologic indications (e.g., Avtozma/biologic entries), document trial and failure or contraindication/intolerance to two listed alternative agents or provide an attestation why trials are inappropriate.

    • List prior biologics or DMARDs tried and outcomes.
    • Attestation allowed when trials are inappropriate.
    Step Therapy

    Prerequisite Part D drug — confirm and document when required

    Some product entries explicitly require prior Part D drug therapy (e.g., everolimus, Besremi, Braftovi); confirm and document use of the prerequisite Part D drug when indicated.

    • Actively check the product entry for 'Prerequisite Therapy' requirement.
    • If required, document prior Part D drug names and trial outcomes.
    Step Therapy

    Caplyta — prior trials of specified oral antipsychotics required

    Caplyta requires a trial and failure, contraindication, or intolerance to specified oral generic atypical antipsychotics for labeled indications prior to approval.

    • Document which oral atypical antipsychotics were tried and reasons they were unsuccessful or contraindicated.
    Step Therapy

    Cabometyx — sorafenib trial/failure documentation required for some RCC uses

    For Cabometyx in some RCC indications, document trial and failure, contraindication, or intolerance to sorafenib prior to approval.

    • Provide details of prior sorafenib therapy and reasons for discontinuation.
    Step Therapy

    Step therapy — document prior therapy trials and failures as specified

    Many products require documented trial and failure (or contraindication/intolerance) to specific prior therapies (examples: Chenodal requires trial/failure of ursodiol; Ciclopirox requires trial/failure of oral terbinafine; Copiktra requires failure of at least two prior CLL/SLL therapies).

    • Provide prior therapy names, dates, and reasons for failure/intolerance.
    • If trials are inappropriate, include clinician attestation explaining rationale.
    Step Therapy

    Cosentyx IV — two‑agent trial requirement for initial approval

    Cosentyx IV initial approval requires trial and failure/contraindication/intolerance to two specified agents (examples include Cosentyx SC and other listed biologics) unless continuation of prior therapy is documented.

    • Document two prior biologic/small molecule comparator trials and outcomes.
    • Alternatively document continuation of previously approved IV therapy.
    Step Therapy

    Prerequisite Part D drug — supply prior‑therapy details when required

    When a product entry states a prerequisite Part D drug is required, include documentation of that prior Part D therapy (agent name, dates, and reason for failure/intolerance) with the PA request.

    • Examples in the policy indicate some products do require prerequisite Part D drugs; confirm per product entry.
    Step Therapy

    Empaveli — document ≥12‑week ACEi/ARB/SGLT2 trial for glomerulopathy indications

    Empaveli for C3G/primary IC‑MPGN requires documentation that the patient was treated with a maximally tolerated dose of an ACE inhibitor, ARB, or SGLT2 inhibitor for at least 12 weeks prior to initiating therapy.

    • Provide medication name(s), dosing, and documentation of the 12‑week trial.
    • Confirm patient age ≥12 for these indications.
    Step Therapy

    Dupixent — document prior controller therapy per age group

    Dupixent PA for asthma/eosinophilic phenotypes requires documentation of prior controller regimens per age group (medium/high‑dose ICS plus additional controller or maximally dosed combination ICS/LABA) unless contraindicated.

    • Include current inhaled controller regimen and justification if unable to trial required controllers.
    • Provide exacerbation or hospitalization history as specified.
    Step Therapy

    Ebglyss — prior topical corticosteroid trial required

    Ebglyss PA requires prior trial/failure/contraindication/intolerance to medium or higher potency topical corticosteroids (and other listed topical agents) before approval.

    • Document the topical corticosteroid trial duration and response or intolerance.
    • Provide weight, BSA/SCORAD, and prescriber specialty information.
    Step Therapy

    Step therapy — document required prior trials or provide attestation

    Many products include step therapy or prerequisite therapy requirements (e.g., ACEi/ARB/SGLT2 for glomerulopathies; conventional DMARDs for RA; topical agents for psoriasis); document trials, failures, and reasons for intolerance or contraindication.

    • List prior agents, trial durations, and objective evidence of failure/intolerance.
    • If trials are not done, include clinician attestation explaining why.
    Note

    Prerequisite Part D drug — verify when NOT required

    Clarifying: several product entries explicitly state that a prerequisite Part D drug is not required for approval; verify the specific product block (e.g., Actimmune).

    • Actimmune: criteria does NOT require use of a prerequisite Part D drug.
    • Check each product entry for whether prerequisite Part D drug is required or not.
    Step Therapy

    Asthma — document trials/intolerance to specified inhaled controller regimens

    For asthma and related indications with step requirements, document trials, intolerance, or contraindication to the specified inhaled corticosteroid regimens and additional controller therapy per age group in the PA submission.

    • For ages 6–11: medium‑dose ICS plus additional controller or medium‑dose ICS/LABA combination.
    • For ≥12: high‑dose ICS plus additional controller or maximally‑dosed combination ICS/LABA.
    Step Therapy

    Fruzaqla — document specified prior chemo, anti‑VEGF, and RAS‑dependent therapy

    Fruzaqla requires prior use of specified chemotherapy regimens and an anti‑VEGF agent; include prior anti‑EGFR therapy and later‑line agents (trifluridine/tipiracil or regorafenib) when RAS wild‑type as applicable.

    • Document prior fluoropyrimidine/oxaliplatin/irinotecan regimens and anti‑VEGF therapy.
    • Provide tumor RAS status and subsequent therapy history per product logic.
    Step Therapy

    Humira — document 3‑month conventional DMARD trial for RA initial requests

    Humira initial RA requests require documentation of a minimum 3‑month trial and failure (or contraindication/intolerance) to a conventional DMARD (methotrexate, leflunomide, or sulfasalazine) at maximally tolerated doses.

    • Provide DMARD trial dates, doses, and reason for failure/intolerance.
    • Continuation requests require demonstration of positive clinical response.
    Step Therapy

    Hyrnuo — prior systemic therapy documentation required

    Hyrnuo criteria require prior systemic therapy; when the product entry indicates a prerequisite Part D drug is required, include documentation of that prior systemic therapy.

    • Document prior systemic therapy names and outcomes.
    • Confirm presence of HER2 activating mutation per testing when applicable.
    Step Therapy

    Step therapy — supply detailed prior therapy history to support PA

    Many products require trial and failure (or contraindication/intolerance) of specified prior therapies — provide detailed prior therapy history (agents, durations, outcomes) with the PA to avoid delays or denials.

    • Examples include requirements for inpatient/outpatient oncology, psychiatric acute agitation agents, Parkinson's OFF episode agents, and conventional IBD therapies.
    • If trials are inappropriate, include clinician attestation explaining rationale.
    Documentation Required

    Actimmune — include required diagnosis documentation

    Provide documentation of the primary diagnosis when requesting Actimmune: chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO).

    • Include clinical records confirming CGD or SMO as required medical information.
    Documentation Required

    PAH products — document right heart catheterization or current PAH therapy

    For PAH products (e.g., Adempas), document whether the diagnosis was confirmed by right heart catheterization or that the patient is currently on therapy for PAH when required by the product entry.

    • Include right heart catheterization confirmation if available, or current PAH therapy details.
    Documentation Required

    Dalfampridine — document MS diagnosis and walking impairment

    For dalfampridine, include a diagnosis of multiple sclerosis and physician confirmation that the patient has difficulty walking (for example, a timed 25‑foot walk) to support the PA.

    • Document the walking impairment assessment and any EDSS score if available.
    Documentation Required

    Arikayce — document persistent MAC after ≥6 months multidrug therapy

    For Arikayce, include documentation that MAC lung disease persists after at least 6 consecutive months of a multidrug background regimen and that sputum cultures did not achieve at least two negatives.

    • Provide microbiology results and prior multidrug regimen details and duration (≥6 months).
    Documentation Required

    Augtyro — include ROS1/NTRK testing and prior therapy history

    For Augtyro, include tumor testing demonstrating ROS1 rearrangement for NSCLC or NTRK fusion for applicable solid tumors, and prior treatment history or lack of satisfactory alternatives when applicable.

    • Submit FDA‑approved or CLIA‑approved test results for ROS1 or NTRK fusions.
    • Document prior therapies and reasons for Augtyro selection.
    Documentation Required

    Avtozma — supply diagnosis, HRCT/biopsy for SSc‑ILD, and prior trials

    For Avtozma PA requests, provide diagnosis‑specific documentation (RA, GCA, SJIA, PJIA, SSc‑ILD) and, for SSc‑ILD, HRCT and/or biopsy consistent with SSc‑ILD; include trials/failures or attestation why trials are inappropriate.

    • Prescriber: rheumatologist or appropriate specialist for initial therapy.
    • Initial coverage commonly 6 months; reauth 12 months with clinical response.
    Documentation Required

    Benlysta — include autoantibody results and concurrent SOC therapy

    For Benlysta initiation in SLE, include documentation of active SLE, positive autoantibody (ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL), and current use of at least one standard‑of‑care therapy.

    • Provide antibody titers and current standard‑of‑care medications.
    Documentation Required

    Ayvakit — include PDGFRA exon‑18 mutation or platelet count for mastocytosis

    For Ayvakit, include the diagnosis and PDGFRA exon 18 mutation (e.g., D842V) or AdvSM/ISM diagnosis and platelet count ≥50 x10^9/L where applicable.

    • Submit genetic testing confirming PDGFRA exon 18 mutation when claiming GIST indication.
    • Provide platelet count and disease subtype documentation for mastocytosis indications.
    Documentation Required

    Balversa — include FGFR3 testing and prior systemic therapy

    For Balversa, include urothelial carcinoma staging and documentation of a susceptible FGFR3 alteration by an FDA‑approved or CLIA‑approved test and prior systemic therapy history.

    • Provide FGFR3 test results and prior systemic therapy dates and outcomes.
    Documentation Required

    Bronchitol — include CF diagnosis and BTT results

    For Bronchitol initial PA, include documentation the patient has cystic fibrosis and that they passed the Bronchitol Tolerance Test (BTT).

    • Attach BTT results and CF diagnosis documentation.
    • Prescriber: pulmonologist or specialist for initial therapy.
    Documentation Required

    Brukinsa — include detailed prior‑therapy history per indication

    For Brukinsa, provide diagnosis and prior therapy history appropriate to the specific indication (e.g., number and type of prior lines of therapy, anti‑CD20 exposure for MZL).

    • List prior regimens and reasons for discontinuation or intolerance.
    • Indicate prescriber specialty if required.
    Documentation Required

    Cablivi — document aTTP, IV administration, and plasma exchange status

    For Cablivi, include diagnosis of aTTP and documentation that the first dose was/will be administered by a healthcare provider as a bolus IV injection and concomitant immunosuppressive/plasma exchange details.

    • Document timing of plasma exchange and immunosuppressive therapy.
    • Confirm hematology/oncology prescriber involvement.
    Documentation Required

    Cabometyx — include tumor diagnosis and prior targeted therapy failures

    For Cabometyx, include diagnosis of the relevant malignancy and documentation of prior targeted therapy failures or contraindications (e.g., prior VEGFR‑targeted therapy or sorafenib as specified).

    • Provide prior targeted therapy names, dates, and reasons for failure/intolerance.
    • Include tumor type and staging documentation.
    Documentation Required

    Calquence — include diagnosis and prior therapy/transplant eligibility details

    For Calquence, provide diagnosis of mantle cell lymphoma or CLL/SLL and documentation of prior therapy status and transplant eligibility as applicable.

    • Document whether patient is treatment‑naïve or previously treated and transplant eligibility details.
    • Include prior therapy regimens and outcomes.
    Documentation Required

    Caplyta — include psychiatric diagnosis and prior agent trial details

    For Caplyta, include the labeled psychiatric diagnosis and documentation of trials and failures, contraindications, or intolerances to the specified alternative agents per indication.

    • Document the specific agents trialed and the clinical rationale for Caplyta initiation.
    • Indicate prescriber specialty if applicable.
    Documentation Required

    Caprelsa — include MTC disease documentation

    For Caprelsa, include documentation of metastatic or unresectable locally advanced medullary thyroid cancer with symptomatic or progressive disease.

    • Provide imaging/pathology and clinical course supporting symptomatic or progressive MTC.
    Documentation Required

    Cayston — include pathogen test and age; show benefit at reauth

    For Cayston, include evidence of Pseudomonas aeruginosa in the lungs and patient age (≥7 years for initial CF use); at reauthorization, provide evidence of clinical benefit.

    • Attach microbiology demonstrating Pseudomonas aeruginosa.
    • Provide clinical response data at reauthorization (improved pulmonary outcomes or fewer exacerbations).
    Documentation Required

    Cerdelga — include CYP2D6 test and Gaucher diagnosis

    For Cerdelga, include an FDA‑cleared CYP2D6 test result showing EM, IM, or PM status and documentation of Gaucher disease type 1; age ≥18 years applies.

    • Attach CYP2D6 test report and confirm patient age and diagnosis.
    • Coverage duration: 12 months.
    Documentation Required

    Cerdelga — required CYP2D6 diagnostic testing

    Provide required diagnostic testing for Cerdelga requests: an FDA‑cleared CYP2D6 test demonstrating metabolizer status (EM/IM/PM) is required to support the PA.

    • Test must be FDA‑cleared or performed at a CLIA‑approved facility.
    • State the detected metabolizer phenotype in the documentation.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    AAT deficiency definitionCongenital AAT deficiency with clinical emphysema plus homozygous PiZZ (or PiZ(null)/Pi(null)(null)) or other rare genotypes associated with pre-treatment serum AAT < 11 µM/L
    Clinical requirementContinued conventional treatment for emphysema (eg, bronchodilators) required
    Measurement equivalents<11 µM/L corresponds to <80 mg/dL by radial immunodiffusion or <57 mg/dL by nephelometry
    inv-276: PAH confirmation (definition)
    PAH confirmation criteriaSymptomatic pulmonary arterial hypertension AND either (A) diagnosis confirmed by right heart catheterization OR (B) patient is currently on therapy for PAH
    Prescriber requirementPrescribed by or in consultation with a pulmonologist or cardiologist for initial PAH/CTEPH requests
    Initial coverage durationInitial: 6 months; Reauth: 12 months (reauth requires positive clinical response)
    inv-277: Timed 25-foot walk test (definition/example)
    Timed 25-foot walk test (example)Physician-confirmed measure of walking difficulty used to support dalfampridine initiation (eg, timed 25-foot walk)
    Associated eligibilityDiagnosis of multiple sclerosis with clinician confirmation of walking impairment; EDSS ≤ 7 or not wheelchair-restricted
    Use in documentationProvider attestation of test or equivalent physician-documented functional limitation acceptable
    inv-278: HRCT patterns for SSc-ILD (definition)
    HRCT patterns for SSc-ILDHRCT showing NSIP, UIP, or centrilobular fibrosis pattern consistent with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
    Biopsy correlationIn patients with lung biopsy, both HRCT and surgical lung biopsy pattern should reveal SSc-ILD or probable SSc-ILD
    Prescriber requirementPrescribed by or in consultation with an appropriate specialist (eg, rheumatologist, pulmonologist)
    inv-279: Autoantibody positive (SLE) — lab definition
    Autoantibody positive (SLE) lab definitionANA titer ≥ 1:80 OR anti-dsDNA level ≥ 30 IU/mL
    Indication useRequired medical information for initiation of Benlysta in active SLE
    Age/prescriber notesPrescribed by or in consultation with a rheumatologist for SLE initiation
    inv-280: Platelet threshold (Ayvakit)
    Platelet threshold (Ayvakit / Doptelet contexts)Policy requires platelet count ≥ 50 x 10^9/L for systemic mastocytosis indications (Ayvakit); Doptelet TPPP threshold is baseline platelet <50,000/mcL and ITP initial <30,000/mcL
    Indication-specific useAyvakit: applies to GIST with PDGFRA exon 18 mutation and AdvSM/ISM; Doptelet: thresholds depend on TPPP vs ITP indication
    Documentation requirementBaseline platelet labs must be provided with prior authorization requests per indication
    inv-281: Bronchitol Tolerance Test (BTT) definition
    Bronchitol Tolerance Test (BTT)A tolerance test that must be passed prior to initial Bronchitol authorization (documented in the PA requirements)
    Initial diagnostic requirementInitial diagnosis of cystic fibrosis required alongside passed BTT
    Prescriber requirementInitial prescriptions should be by or in consultation with a pulmonologist or specialist
    inv-282: aTTP definition
    aTTP definition (Cablivi)Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) requiring first dose administered by healthcare provider as bolus IV and used with immunosuppressive therapy; plasma exchange status documented
    Administration detailFirst dose administered as bolus IV by a healthcare provider; used with immunosuppressive therapy and with/after plasma exchange per criteria
    Prescriber restrictionPrescribed by or in consultation with a hematologist or oncologist
    inv-283: CYP2D6 metabolizer status requirement (definition)
    CYP2D6 metabolizer status requirementCYP2D6 metabolizer phenotype (EM, IM, or PM) determined by an FDA-cleared test is required documentation for Cerdelga prescribing
    Age requirementFor Gaucher disease entry, patient must be 18 years of age or older
    PurposeTest result used to confirm appropriate metabolism category before initiating therapy
    inv-284: Onychomycosis confirmation (definition)
    Onychomycosis confirmationDiagnosis must be confirmed by KOH preparation, culture, or histology for ciclopirox nail lacquer coverage
    Disease extent requirementToenail onychomycosis: mild-to-moderate disease involving at least 1 target toenail; No lunula (matrix) involvement
    Prior therapy requirementTrial and failure/contraindication/intolerance to oral terbinafine required (≥6 weeks fingernails; ≥12 weeks toenails)
    inv-285: Moderate to severe plaque psoriasis (definition)
    Moderate-to-severe plaque psoriasis definitionAt least 3% BSA involvement OR severe scalp psoriasis OR palmoplantar/facial/genital involvement (with prior topical trial)
    Prior topical therapyMinimum 4-week trial and failure/contraindication/intolerance to a topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor
    PrescriberPrescribed by or in consultation with a dermatologist for plaque psoriasis and HS initial uses
    inv-286: Active nr-axSpA with objective signs of inflammation (definition)
    Active nr-axSpA definitionNon-radiographic axial spondyloarthritis with objective signs of inflammation (eg, elevated CRP and/or sacroiliitis on MRI) without definitive radiographic structural damage
    Prior NSAID trialMinimum 1-month trial and failure/contraindication/intolerance to one NSAID for AS; for nr-axSpA TF/C/I to two NSAIDs often required
    Prescriber requirementPrescribed by or in consultation with a rheumatologist
    inv-287: Muscle spasm (definition)
    Muscle spasm definitionDiagnosis of muscle spasm associated with acute, painful musculoskeletal conditions (indication for cyclobenzaprine)
    Risk acknowledgementPrescriber must acknowledge anticholinergic risks and consider dose reduction or discontinuation of other anticholinergic meds
    Coverage durationTypical course: 4 weeks for acute muscle spasm or TMJ-related use
    inv-288: Fibromyalgia (off-label) (definition)
    Fibromyalgia (off-label) usage noteListed as an off-label indication for symptom management (eg, difficulty sleeping); prescriber acknowledgement and PA apply for patients ≥65
    Coverage durationWhen approved, coverage duration listed as 12 months in this excerpt
    RequirementPrescriber should document rationale given off-label status
    inv-289: Acute temporomandibular disorder (off-label)
    Acute temporomandibular disorder (off-label)Requires diagnosis of acute TMD, pain on palpation of the lower jaw muscle, and use in combination with an NSAID (eg, naproxen)
    Coverage durationShort course (4 weeks) for acute TMJ management per excerpt
    Prescriber notesPA applies to patients 65+ and prescriber should document combined therapy rationale
    inv-290: Eosinophilic asthma / Type 2 inflammation (definition)
    Eosinophilic asthma / Type 2 inflammationAsthma phenotype defined by baseline peripheral blood eosinophils ≥150 cells/mcL for certain Dupixent indications (and ≥300 cells/mcL for COPD in other sections)
    Clinical requirementsPlus history of exacerbations (eg, ≥2 systemic steroid courses or asthma-related hospitalization in past 12 months) and age/therapy-specific controller trials
    PrescriberPrescribed by or in consultation with a pulmonologist or allergist/immunologist
    inv-291: TPPP (Thrombocytopenia Prior to Planned Procedure) definition
    TPPP definitionThrombocytopenia prior to planned procedure: thrombocytopenia in a patient with chronic liver disease scheduled for a procedure with baseline platelet count <50,000/mcL
    Intended useShort-term coverage (eg, Doptelet TPPP: 1 month) to raise platelet counts for procedures
    Prescriber requirementPrescribed by or in consultation with relevant specialist per product criteria
    inv-292: PNH definition (Empaveli)
    PNH definition (Empaveli)Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) required for Empaveli initiation
    PrescriberPrescribed by or in consultation with a hematologist or oncologist
    Coverage durationInitial and reauthorization coverage: 12 months; reauth requires positive clinical response
    inv-293: C3G / primary IC-MPGN definition
    C3G / primary IC-MPGN definitionDiagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative GN (IC-MPGN); for primary IC-MPGN patient must not have had a kidney transplant
    Prerequisite therapyPatient must have been treated with maximally tolerated ACE inhibitor, ARB, or SGLT2 inhibitor for at least 12 weeks prior to Empaveli initiation
    Age requirementPatient is 12 years of age or older for these indications
    inv-294: Anemia (policy thresholds)
    Anemia policy thresholds (initial)Hematocrit < 36% or hemoglobin < 12 g/dL for initial requests (general anemia definitions in policy)
    Reauthorization lab windowReauth: most recent or average Hct over 3 months ≤ 36% OR most recent or average Hgb over 3 months ≤ 12 g/dL
    Context-specific thresholdsCertain indications use different thresholds (eg, CKD/chemo: Hct <30% or Hgb <10 g/dL); see product-specific criteria
    inv-295: Adequate iron stores (definition)
    Adequate iron stores definitionFerritin > 100 mcg/L AND transferrin saturation (TSAT) > 20% required for certain epoetin alfa indications
    Documentation timingIron studies should be documented as part of the laboratory evidence required at initiation (within specified windows)
    Applies toCKD, HIV, chemo, preop, and MDS initial indication requirements per epoetin alfa criteria
    inv-296: Serum erythropoietin requirement (definition)
    Serum erythropoietin requirementSerum erythropoietin (EPO) ≤ 500 mU/mL required for some indications (eg, HIV, MDS) for epoetin alfa initiation
    AlternativeTransfusion‑dependent MDS diagnosis may substitute where applicable
    TimingEPO level should be documented within the laboratory evidence required for initial request
    inv-297: FIP1L1-PDGFRA-negative (definition)
    FIP1L1-PDGFRA-negative requirementPatients with HES must be FIP1L1-PDGFRA-negative to qualify for coverage
    Secondary causes excludedOther non-hematologic secondary causes (eg, drug hypersensitivity, parasites, HIV, non-hematologic malignancy) must be ruled out
    Pre-treatment eosinophil countPre-treatment blood eosinophil count ≥ 1000 cells/µL required for HES initial requests
    inv-298: Eosinophilic asthma phenotype (definition)
    Eosinophilic asthma phenotypeAsthma with baseline pre-treatment peripheral blood eosinophil level ≥ 150 cells/µL
    Exacerbation history requirementPlus either ≥2 exacerbations requiring systemic corticosteroids in past 12 months or prior asthma-related hospitalization
    Age and controller therapy criteriaAge- and therapy-specific controller regimens required per age group prior to approval
    inv-299: Tumor RAS status (Fruzaqla)
    Tumor RAS status categoriesTumor RAS mutant OR RAS wild-type (used to determine subsequent prior therapy sequencing for Fruzaqla)
    Prior therapy dependenceIf RAS wild-type, prior anti-EGFR therapy and later-line therapies may be required per product-specific sequencing
    DocumentationMedical record must document RAS status and prior chemotherapy/biologic exposures as specified
    inv-300: Gavreto eligibility test requirement (RET fusion-positive)
    Gavreto eligibility test requirementRET gene fusion–positive tumor detected by an FDA-approved test or a CLIA-approved laboratory test is required
    IndicationsNSCLC or advanced thyroid cancer with RET fusion–positive tumors; for thyroid cancer patient must be radioactive iodine‑refractory or RAI inappropriate
    Age restrictionThyroid cancer indication: patient age ≥ 12 years
    inv-301: All Medically-accepted Indications (definition)
    All Medically-accepted Indications meaningProduct may be requested for any FDA- or otherwise medically-accepted indication subject to the listed PA requirements
    PA applicabilityEach indication still requires diagnosis-specific documentation, prescriber/biomarker requirements, and coverage-duration rules
    ContinuationMany products allow continuation of prior therapy when prior authorization criteria were previously met
    inv-302: AGHD and GH stimulation tests (definition)
    AGHD and GH stimulation testsAdult GHD confirmation requires GH stimulation tests (eg, ITT ≤ 5 mcg/L, glucagon ≤ 3 mcg/L, macimorelin ≤ 2.8 ng/mL at specified timepoints)
    Alternative confirmationDocumentation of deficiency of three anterior pituitary hormones plus low IGF‑1 may also support diagnosis
    PrescriberPrescribed by or in consultation with an endocrinologist for AGHD and related indications
    inv-303: Test demonstrating targetable mutation (ROS1/IDH2 requirement)
    Test demonstrating targetable mutationPresence of ROS1 rearrangement or IDH2 mutation must be detected by an FDA-approved test or a CLIA‑approved laboratory test for the respective product indications
    PurposeRequired to establish eligibility for targeted agents (eg, Ibtrozi for ROS1; Idhifa for IDH2)
    DocumentationTest report from FDA-cleared or CLIA‑approved laboratory must be provided with PA request
    inv-304: TF/C/I (Trial and failure / Contraindication / Intolerance) definition
    TF/C/I definitionTrial and failure, contraindication, or intolerance to specified conventional therapies as required per disease-specific criteria (eg, 2 biologics or 2 NSAIDs where listed)
    Typical applicationUsed across product criteria to require prior trials of specified agents before approval (eg, Cosentyx IV, Humira, many oncology/non-oncology agents)
    DocumentationPA requests must document prior trial durations and outcomes or provide rationale why trials are inappropriate